These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23400750)

  • 21. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
    Williams BG; Abdool Karim SS; Karim QA; Gouws E
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
    Mansoor LE; Abdool Karim Q; Yende-Zuma N; MacQueen KM; Baxter C; Madlala BT; Grobler A; Abdool Karim SS
    AIDS Behav; 2014 May; 18(5):811-9. PubMed ID: 24643315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
    Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
    AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
    Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient.
    Mcconville C; Friend DR; Clark MR; Malcolm K
    J Pharm Sci; 2013 Jun; 102(6):1859-1868. PubMed ID: 23568749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
    Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
    AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
    Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
    AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
    Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
    J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
    Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
    N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
    Yang KH; Hendrix C; Bumpus N; Elliott J; Tanner K; Mauck C; Cranston R; McGowan I; Richardson-Harman N; Anton PA; Kashuba AD
    PLoS One; 2014; 9(10):e106196. PubMed ID: 25350119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
    Carballo-Diéguez A; Balán IC; Morrow K; Rosen R; Mantell JE; Gai F; Hoffman S; Maslankowski L; El-Sadr W; Mayer K
    AIDS Care; 2007 Sep; 19(8):1026-31. PubMed ID: 17852000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
    Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
    AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.
    McBride JW; Dias N; Cameron D; Offord RE; Hartley O; Boyd P; Kett VL; Malcolm RK
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
    Adams JL; Kashuba AD
    Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):451-62. PubMed ID: 22306523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of topical antiretroviral chemoprophylaxis.
    Van Damme L; Szpir M
    Curr Opin HIV AIDS; 2012 Nov; 7(6):520-5. PubMed ID: 22918449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Test of new vaginal microbicide gel show promise for women.
    AIDS Read; 2008 Apr; 18(4):165-6. PubMed ID: 18467997
    [No Abstract]   [Full Text] [Related]  

  • 37. Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.
    Miller L; Prieto Merino D; Baisley K; Hayes R
    PLoS One; 2022; 17(5):e0267011. PubMed ID: 35551324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
    Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.
    Chaturvedula A; Fossler MJ; Hendrix CW
    J Clin Pharmacol; 2014 Feb; 54(2):150-60. PubMed ID: 24203458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.